BACKGROUND AND PURPOSE Antiplatelet drug resistance has been associated with thromboembolic complications in patients after coronary stent placement. It has not been well-studied in patients who have neurovascular stent-placement procedures. This study aimed to analyze the relationship between antiplatelet drug resistance and neurovascular stent-placement complications. MATERIALS AND METHODS ...

AIMS Antiplatelet therapy with aspirin and clopidogrel is recommended for 1 year after drug-eluting stent (DES) implantation or myocardial infarction. However, the discontinuation of antiplatelet therapy has become an important issue as recent studies have suggested a clustering of ischemic events within 90 days of clopidogrel withdrawal. The objective of this investigation was to explore the h...

Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events. Although clinical guidelines recommend aspirin lifelong and clopidogrel for between one and 12 months, depending upon the indication, the optimal duration of c...

Background: Coronary Artery Disease (CAD) is one of the largest causes mortality worldwide. Clopidogrel, antiplatelet drug, has been widely used for management CAD. The current study aimed to investigate effect clopidogrel on oxidative stress in CAD patients. Methods: One hundred patients, who were followed-up 5 days after receiving clopidogrel, and 50 healthy volunteers included this study. Pa...

Objetivo: Debater sobre o uso mais efetivo da antiagregação plaquetária após intervenção coronária percutânea. Métodos: A abordagem metodológica deste trabalho se propõe a um compilado de pesquisa bibliográfica qualitativa e caráter descritivo por meio uma revisão integrativa literatura nas bases dados PubMed Biblioteca Virtual em Saúde. Os descritores utilizados foram Platelet Aggregation Inhi...

Proton pump inhibitors often are prescribed in combination with clopidogrel to decrease risk of gastrointestinal bleeding after acute coronary syndrome. Clopidogrel is a prodrug that has to be metabolized in the liver to generate the active metabolite. Both medications are metabolized largely by the CYP2C19 enzyme; therefore, concerns exist that a drug-drug interaction during concomitant treatm...

OBJECTIVES We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes. BACKGROUND Low platelet inhibition by clopidogrel is associated with ischemic clinical events. A higher 600-mg loading dose (LD) has been advocated to increase responsiveness to clopidogrel. METHODS In this study, 110 aspirin...

BACKGROUND Incidence and predictors of clopidogrel discontinuation after drug eluting stent (DES) implantation, in real world practice, are poorly known. METHODS Prospective study included all patients who underwent implantation of at least one DES between February 2006 and January 2007. Predictors of clopidogrel discontinuation were assessed by a multivariable analysis. RESULTS In 269 pati...

Objective: The objective of the study was to perform a Non linear mixed-effects analysis of the pharmacokinetics of clopidogrel, to study the effect of covariates like age, body surface area and creatinine clearance on the population pharmacokinetics of clopidogrel in South Indian Cardiac patients. Methods: A simple, rapid and sensitive isocratic HPLC-UV method for detection and quantification ...

The P2Y12 receptor plays a crucial role in the regulation of platelet activation by several agonists, which is irreversibly antagonized by the active metabolite of clopidogrel, a widely used anti-thrombotic drug. In this study, we investigated whether reduction of platelet reactivity leads to reduced inflammatory responses using a rat model of erosive arthritis. We evaluated the effect of clopi...